By: Benzinga
Social Market Analytics Looks at Sentiment Surrounding Upgrades for Dendreon
This week, Social Market Analytics (SMA) looks at Dendreon Corp. (NASDAQ: DNDN ), a biotechnology company with an emerging product portfolio of novel therapeutics to enhance cancer treatment options for patients, most notably Provenge for the treatment of prostate cancer. The week of January 7 yielded very positive results
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here